TD Cowen maintains Calumet at Hold, lowers price target to $37 from $40

TD Cowen kept its Hold rating on Calumet but reduced its price target from $40 to $37, a 7.5% cut. This new target suggests a 16.3% upside from the Nov 17 closing price of $31.82, according to the firm.

Original reporting
Published Nov 18, 2026, 2:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 2:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TD Cowen maintains Calumet at Hold, lowers price target to $37 from $40 — source image
Decision brief

The 30-second read

$CLMTBearishLow
01

Why it matters

A lower price target can shift near-term sentiment and expectations, but the unchanged Hold rating suggests the analyst does not see a strong catalyst for a directional re-rating.

02

Market read

Useful for traders tracking sell-side sentiment, but it is not a standalone fundamental catalyst.

03

What to watch

Traders may already price in analyst target changes; without new operational data, the impact may fade quickly unless other firms issue similar downgrades.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication time, for same-day positioning

Background

The piece is an analyst action update from TD Cowen on Calumet, not a company disclosure.

Company-level read

Ticker impact

$CLMTBearishMedium confidence
Context

TD Cowen maintained Calumet at Hold and cut its price target to $37 from $40, implying a lower valuation for CLMT.

Expected impact

Likely mild downward pressure or reduced upside expectations as the market digests the lower target, with limited follow-through risk given the unchanged Hold.

Evidence & confidence

The article provides a specific, time-relevant analyst action (PT cut) but no new company fundamentals or catalyst beyond the rating update.

Market effects

Minimal, as this is a single-name analyst target change with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the rating stays at Hold, the PT cut may be more about valuation than a new deterioration in fundamentals, limiting downside follow-through.

Key entities

  • Calumet

    Subject of the analyst action, with a Hold rating and a reduced price target.

  • TD Cowen

    Brokerage issuing the maintained rating and lowered target.

Related articles

$CLMTHighAI 8/10

Calumet (CLMT) Q3 2026 Earnings Call Transcript

Calumet (CLMT) reported Q3 2026 earnings with adjusted EBITDA of $347.2M, up from $92.5M in Q3 2025. Net income was $273.3M, down from $313.4M YoY. The company retired $265M in debt, reducing annual interest by $26M. Specialty Products and Solutions EBITDA was $248.1M, while Montana Renewables EBITDA was $110.6M. Management highlighted debt reduction, strategic restructuring, and plans to increase sustainable aviation fuel production.

$CLMTMed

What Calumet (CLMT) Said on Its Q3 Earnings Call

Calumet (CLMT) reported Q3 earnings, highlighting a completed turnaround at its Shreveport facility and progress on Montana Renewables' expansion. Adjusted EBITDA for Montana Renewables was $110.6M, with CMR contributing $40.8M. The company plans to increase sustainable aviation fuel production, with a path to 200M gallons annually by 2028. Debt reduction remains a priority, with $175M in 2028 notes outstanding.

$CLMTHighAI 8/10

Calumet Reports Third Quarter 2026 Results

Calumet, Inc. /DE (CLMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calumet Reports Third Quarter 2026 Results • Third Quarter 2026 net income of $273.3 million, or basic earnings per common share of $2.91 • Third Quarter 2026 Adjusted EBITDA with Tax Attributes of $347.2 million • Accelerated deleveraging continues with approximatel